Dilation of the Infarct-Related Coronary Artery to Reduce the Incidence of the No-Reflow Phenomenon in STEMI Patients

   Background: The pathogenesis of slow/no-reflow phenomena is a critical socio-medical problem due to high mortality and work disability rates in patients with ST-segment elevation myocardial infarction (STEMI). Slow/no-reflow phenomena are multifactorial involving 4 key elements: 1) distal embolization of the coronary bed of the infarct-related coronary artery; 2) ischemic damage to the myocardium; 3) reperfusion injury of the heart muscle; 4) individual (genetic) susceptibility of the microcirculation to injury.

   Objective: To analyze the outcomes of percutaneous coronary interventions (PCI) in patients with STEMI and TIMI 0 blood flow of an infarct-related coronary artery based on the strategy to restore antegrade blood flow (balloon predilation or dilation of an infarctrelated artery).

   Materials and methods: We analyzed treatment outcomes of 209 patients with STEMI and TIMI 0 blood flow. The patients were grouped based on the PCI strategy: group 1 included 147 patients who underwent balloon angioplasty to restore antegrade blood flow, and group 2 included 62 patients who underwent dilation of an infarct-related coronary artery.

   Results: Our study found that direct stenting in STEMI patients was associated with statistically significantly lower risk of slow/noreflow phenomena (P = 0.001, Pearson’s χ²) and, as a result, better functional outcomes of treatment (chronic heart failure grade classified according to Strazhesko-Vasilenko and by left ventricular ejection fraction) that were also statistically significant (P = 0.001, Pearson’s χ²).

   Conclusions: Our study demonstrated that the risk of slow/no-reflow phenomena in patients with TIMI 0 blood flow of an infarctrelated coronary artery was statistically significantly lower (P = .001, Pearson’s χ²) in the group of patients who underwent dilation of an infarct-related coronary artery to restore antegrade blood flow. Functional outcomes (chronic heart failure grade and overall survival) were also better in this group of patients (P = .001, Pearson’s Chi-square). Moreover, dilation of an infarct-related coronary artery was associated with preserved left ventricular ejection fraction compared with the group of patients who underwent balloon angioplasty to restore antegrade blood flow (P < 0.001, Pearson’s χ²).

1. Alekyan BG, ed. Endovascular Surgery. Textbook: Four-Volume Edition. Vol 2. Ischemic Heart Disease. Litterra; 2017:399–426. (In Russ.).

2. Sazanov GV, Belokon’ OS. The effect of predilation on the incidence of the no/slow-reflow phenomenon in patients with acute coronary syndrome with ST segment elevation. Kazan Medical Journal. 2020;101(2):284–288. (In Russ.). doi: 10.17816/KMJ2020-284

3. Ma M, Wang L, Diao KY, et al. A randomized controlled clinical trial of prolonged balloon inflation during stent deployment strategy in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a pilot study. BMC Cardiovasc Disord. 2022;22(1):30. PMID: 35120436. PMCID: PMC8815170. doi: 10.1186/s12872-022-02477-0

4. Montone RA, Camilli M, Del Buono MG, et al. No-reflow: update on diagnosis, pathophysiology and therapeutic strategies. G Ital Cardiol (Rome). 2020;21(6 suppl 1):4S–14S. (In Italian). PMID: 32469339. doi: 10.1714/3373.33487

5. Iskhakov MM, Tagirova DR, Gazizov NV, Nugaybekova LA, Sayfutdinov RG. «No-reflow» phenomenon: clinical aspects of reperfusion failure. Kazan Medical Journal. 2015;96(3):391–396. (In Russ.). doi: 10.17750/KMJ2015-391

6. Yaméogo NV, Guenancia C, Porot G, et al. Predictors of angiographically visible distal embolization in STEMI. Herz. 2020;45(3):288–292. PMID: 29926119. doi: 10.1007/s00059-018-4723-1.

7. Heusch G, Skyschally A, Kleinbongard P. Coronary microembolization and microvascular dysfunction. Int J Cardiol. 2018;258:17–23. PMID: 29429637. doi: 10.1016/j.ijcard.2018.02.010

8. Zhuravlev AS, Azarov AV, Semitko SP, Ioseliani DG. The noreflow phenomenon during primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction due to massive coronary thrombosis. Pathogenesis and predictors of no-reflow. Kardiologiia. 2021;61(2):99–105. (In Russ.). doi: 10.18087/cardio.2021.2.n1175

9. Claeys MJ, Bosmans J, De Ceuninck M, et al. Effect of intracoronary adenosine infusion during coronary intervention on myocardial reperfusion injury in patients with acute myocardial infarction. Am J Cardiol. 2004;94(1):9–13. PMID: 15219500. doi: 10.1016/j.amjcard.2004.03.021

10. Zhou H, He XY, Zhuang SW, et al. Clinical and procedural predictors of no-reflow in patients with acute myocardial infarction after primary percutaneous coronary intervention. World J Emerg Med. 2014;5(2):96–102. PMID: 25215156. PMCID: PMC4129879. doi: 10.5847/wjem.j.issn.1920-8642.2014.02.003

11. Reffelmann T, Kloner RA. The no-reflow phenomenon: a basic mechanism of myocardial ischemia and reperfusion. Basic Res Cardiol. 2006;101(5):359–372. PMID: 16915531. doi: 10.1007/s00395-006-0615-2

12. Wu MY, Yiang GT, Liao WT, et al. Current mechanistic concepts in ischemia and reperfusion injury. Cell Physiol Biochem. 2018;46(4):1650–1667. PMID: 29694958. doi: 10.1159/000489241

13. Wang J, Toan S, Zhou H. New insights into the role of mitochondria in cardiac microvascular ischemia/reperfusion injury. Angiogenesis. 2020;23(3):299–314. PMID: 32246225. doi: 10.1007/s10456-020-09720-2

14. Li Y, Palmer A, Lupu L, Huber-Lang M. Inflammatory response to the ischaemia-reperfusion insult in the liver after major tissue trauma. Eur J Trauma Emerg Surg. 2022;48(6):4431–4444. PMID: 35831749. PMCID: PMC9712415. doi: 10.1007/s00068-022-02026-6

15. Yalcin Y, Biyik I, Akturk E, et al. Association between endothelial nitric oxide synthase gene polymorphism (Glu298Asp) and coronary no-reflow phenomenon in acute myocardial infarction. Advances in Hygiene and Experimental Medicine. 2019;73:529–535. doi: 10.5604/01.3001.0013.5253

16. Ashoori A, Pourhosseini H, Ghodsi S, et al. CHA2DS2-VASc score as an independent predictor of suboptimal reperfusion and short-term mortality after primary PCI in patients with acute ST segment elevation myocardial infarction. Medicina (Kaunas). 2019;55(2):35. PMID: 30717292. PMCID: PMC6409514. doi: 10.3390/medicina55020035

17. Ipek G, Onuk T, Karatas MB, et al. CHA2DS2-VASc score is a predictor of no-reflow in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous intervention. Angiology. 2016;67(9):840–845. (In English, Spanish). PMID: 26685178. doi: 10.1177/0003319715622844

18. Mirbolouk F, Gholipour M, Salari A, et al. CHA2DS2-VASc score predict no-reflow phenomenon in primary percutaneous coronary intervention in primary percutaneous coronary intervention. J Cardiovasc Thorac Res. 2018;10(1):46–52. PMID: 29707178. PMCID: PMC5913693. doi: 10.15171/jcvtr.2018.08

19. Namazi M, Mahmoudi E, Safi E, et al. The no-reflow phenomenon: is it predictable by demographic factors and routine laboratory data?. Acta Biomed. 2021;92(5):e2021297. PMID: 34738591. PMCID: PMC8689329 doi: 10.23750/abm.v92i5.10053

20. Kim BG, Cho SW, Seo J, et al. Effect of direct stenting on microvascular dysfunction during percutaneous coronary intervention in acute myocardial infarction: a randomized pilot study. J Int Med Res. 2022;50(9):1–9. PMID: 36177850. PMCID: PMC9528029. doi: 10.1177/03000605221127888